PDF(Pubmed)
Abstract：
The development of systemic treatment options leveraging the molecular landscape of advanced thyroid cancer is a burgeoning field. This is a multidisciplinary evidence-based statement on the definition of advanced thyroid cancer and its targeted systemic treatment.
An expert panel was assembled, a literature review was conducted, and best practice statements were developed. The modified Delphi method was applied to assess the degree of consensus for the statements developed by the author panel.
A review of the current understanding of thyroid oncogenesis at a molecular level is presented and characteristics of advanced thyroid cancer are defined. Twenty statements in topics including the multidisciplinary management, molecular evaluation, and targeted systemic treatment of advanced thyroid cancer are provided.
With the growth in targeted treatment options for thyroid cancer, a consensus definition of advanced disease and statements regarding the utility of molecular testing and available targeted systemic therapy is warranted.
An expert panel was assembled, a literature review was conducted, and best practice statements were developed. The modified Delphi method was applied to assess the degree of consensus for the statements developed by the author panel.
A review of the current understanding of thyroid oncogenesis at a molecular level is presented and characteristics of advanced thyroid cancer are defined. Twenty statements in topics including the multidisciplinary management, molecular evaluation, and targeted systemic treatment of advanced thyroid cancer are provided.
With the growth in targeted treatment options for thyroid cancer, a consensus definition of advanced disease and statements regarding the utility of molecular testing and available targeted systemic therapy is warranted.
摘要：
利用晚期甲状腺癌的分子景观开发系统治疗方案是一个新兴的领域。这是对晚期甲状腺癌的定义及其靶向全身治疗的多学科循证陈述。
组建了一个专家小组，进行了文献综述，并制定了最佳实践声明。改进的德尔菲法用于评估作者小组提出的陈述的共识程度。
综述了目前在分子水平上对甲状腺肿瘤发生的认识，并定义了晚期甲状腺癌的特征。包括多学科管理在内的二十个主题声明，分子评价，并提供晚期甲状腺癌的靶向全身治疗。
随着甲状腺癌靶向治疗方案的增加，对于晚期疾病的共识定义以及有关分子检测的实用性和可用的靶向全身治疗的陈述是必要的.
组建了一个专家小组，进行了文献综述，并制定了最佳实践声明。改进的德尔菲法用于评估作者小组提出的陈述的共识程度。
综述了目前在分子水平上对甲状腺肿瘤发生的认识，并定义了晚期甲状腺癌的特征。包括多学科管理在内的二十个主题声明，分子评价，并提供晚期甲状腺癌的靶向全身治疗。
随着甲状腺癌靶向治疗方案的增加，对于晚期疾病的共识定义以及有关分子检测的实用性和可用的靶向全身治疗的陈述是必要的.
